Trial purpose
Cancer treatment
Tumor type
Genitourinary
Age
18+
Clinical summary
Summary
Eligible patients will be randomised to receive 177Lu-PSMA every 6 weeks for 2 cycles, followed by docetaxel (6 weeks later) every 3 weeks for 6 cycles; OR docetaxel (on its own) every 3 weeks for 6 cycles.
Conditions
This trial is treating people with prostate cancer
Eligibility
Inclusion
Inclusion Criteria for study registration:
- Patient has provided written informed consent
- Male aged 18 years or older at screening
- Prostate cancer diagnosed within 12 weeks of commencement of screening
- Histologically or cytologically confirmed adenocarcinoma of the prostate without significant neuroendocrine differentiation or small cell histology OR metastatic disease typical of prostate cancer (i.e. involving bone or pelvic lymph nodes or para-aortic lymph nodes) with a rising serum PSA
- Evidence of metastatic disease on CT and/or bone scan
- PSA > 10ng/ml prior to commencement of medical ADT or surgical orchidectomy
-
Adequate haematological, renal and hepatic functions as defined by:
- Absolute neutrophil count >1.5 x 109/L
- Platelet count >100 x 109/L
- Haemoglobin ≥ 90g/L (no red blood cell transfusion in 4 weeks prior to randomisation)
- Creatinine Clearance ≥ 40mL/min (Cockcroft-Gault formula)
- Total bilirubin < 1.5 x ULN (unless known or suspected Gilbert syndrome)
- Aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2.0 x ULN (or ≤ 5.0 x ULN in the presence of liver metastases)
- Have a performance status of 0-2 on the ECOG Performance Scale (see Appendix 1)
- Life expectancy greater than 6 months with treatment
- Assessed by a medical oncologist as suitable for treatment with docetaxel
- Patients must agree to use an adequate method of contraception
- Willing and able to comply with all study requirements, including all treatments and required assessments including follow-up
Inclusion Criteria for Randomisation:
- Significant PSMA avidity on 68Ga-PSMA PET/CT, defined after central review as a minimum uptake of SUVmax 15 at a site of disease
- High-volume metastatic disease on 68Ga-PSMA PET/CT defined as visceral metastases or ≥ 4 bone metastases with ≥ 1 outside the vertebral column and pelvis (extra-axial skeleton)
- Patient continues to meet all the inclusion criteria for registration
Exclusion
Exclusion Criteria for Registration:
-
Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer. The following exceptions are permitted:
- Up to 4 weeks of ADT with luteinising hormone releasing hormone agonists or antagonists or orchiectomy ± concurrent anti-androgens are permitted prior to commencement of screening. At investigator discretion, patients may start ADT at commencement of protocol therapy
- Up to one course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 14 days prior to registration
- Symptomatic cord compression, or clinical or imaging findings concerning for impending cord compression
- Central nervous system metastases
- Patients with Sjogren's syndrome
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
-
Prior diagnosis of another cancer that was:
- More than 3 years prior to current diagnosis with subsequent evidence of disease recurrence or clinical expectation of recurrence greater than 10%
- Within 3 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or adequately treated non-muscle invasive bladder cancer (Tis, Ta and low grade T1 tumours)
Exclusion Criteria for Randomisation:
- Major FDG-PET discordance defined as presence of FDG positive disease with minimal PSMA expression in multiple sites (>5) or in more than 50% of total disease volume
- All the exclusion criteria for registration continue to not apply
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- You have been diagnosed with cancer, but have not received any treatment.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Peter MacCallum Cancer Centre
Scientific Title
A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information